Search
Myriad Genetics Inc
MYGNAdd to Watchlist
2.860USD
-2.510-46.74%
Close 07-31 16:00（ET）Quotes delayed by 15 min
273.56MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Myriad Genetics Inc is 5.82, ranking 181 out of 199 in the Healthcare Equipment & Supplies industry. The average price target is 8.00, with a high of 18.00 and a low of 3.50.
Analyst Rating
Based on
10
analysts
Hold
Current Rating
6.000
Target Price
+109.79%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
7
Median
9
Average
Company name
Ratings
Analysts
Myriad Genetics Inc
MYGN
10
Medtronic PLC
MDT
34
Stryker Corp
SYK
32
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
29
1
2
3
...
22
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Myriad Genetics Inc's expected revenue for the next quarter?
Myriad Genetics Inc's expected revenue is 217.43M.
What is Myriad Genetics Inc's price target?
Analysts forecast that Myriad Genetics Inc's price target is USD 8.00, with the highest forecast at USD 18.00 and the lowest forecast at USD 3.50.
How have Myriad Genetics IncMYGN's recent earnings per share performed?
The market expectation was USD -0.46, while Myriad Genetics IncMYGN's earnings per share (EPS) for the previous quarter was USD -0.36. EPS for the next quarter is expected at USD 0.07.
What is the analyst rating for Myriad Genetics Inc?
Based on the ratings of Myriad Genetics Inc's stock from 10 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.